Association of blood glucose level and prognosis of inpatients with coexistent diabetes and COVID-19

Weiwei Duan; Liangyu Li; Xuesong Li; Mengyan Zhu; Lingxiang Wu; Wei Wu; Kening Li; Yuan Liang; Rong Ding; Wenhua You; Ziyu Wang; Bin Huang; Min Wu; Tingting Zhang; Jie Li; Yan Li; Jiaofang Shao; Changsong Lin; Pengping Li; Qianghu Wang; Shukui Wang; Xinyi Xia; Yu Liu; Sali Lyu

doi:10.1007/s12020-021-02923-7

Association of blood glucose level and prognosis of inpatients with coexistent diabetes and COVID-19

Endocrine. 2022 Jan;75(1):1-9. doi: 10.1007/s12020-021-02923-7. Epub 2021 Oct 30.

Authors

Weiwei Duan^#^{1

2

3

4}, Liangyu Li^#^{5

6}, Xuesong Li^#⁷, Mengyan Zhu^#^{5

6}, Lingxiang Wu^{5

6}, Wei Wu^{5

6}, Kening Li^{5

6}, Yuan Liang^{5

6}, Rong Ding^{5

6}, Wenhua You^{5

6}, Ziyu Wang^{5

6}, Bin Huang^{5

6}, Min Wu^{5

6}, Tingting Zhang^{5

6}, Jie Li^{5

6}, Yan Li^{5

6}, Jiaofang Shao^{5

6}, Changsong Lin^{5

6}, Pengping Li^{5

6}, Qianghu Wang^{5

6

8

9}, Shukui Wang¹⁰, Xinyi Xia^{11

12}, Yu Liu¹³, Sali Lyu^{14

15

16

17}

Affiliations

¹ Research Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China. passion@njmu.edu.cn.
² Department of Bioinformatics, Nanjing Medical University, Nanjing, China. passion@njmu.edu.cn.
³ Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, China. passion@njmu.edu.cn.
⁴ Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China. passion@njmu.edu.cn.
⁵ Research Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
⁶ Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
⁷ Key Laboratory of Cardiovascular and Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, China.
⁸ Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, China.
⁹ Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.
¹⁰ Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
¹¹ COVID-19 Research Center, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing Clinical College of Southern Medical University, Nanjing, China. xinyixia@nju.edu.cn.
¹² Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan Huoshenshan Hospital, Wuhan, Hubei, 430100, China. xinyixia@nju.edu.cn.
¹³ Department of Endocrinology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China. drliuyu@njmu.edu.cn.
¹⁴ Research Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China. lvsali@njmu.edu.cn.
¹⁵ Department of Bioinformatics, Nanjing Medical University, Nanjing, China. lvsali@njmu.edu.cn.
¹⁶ Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, China. lvsali@njmu.edu.cn.
¹⁷ Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China. lvsali@njmu.edu.cn.

^# Contributed equally.

Abstract

Type 2 diabetes (T2D) increases the risk of coronavirus disease (COVID-19). This study investigates the association between glucose control of COVID-19 patients with T2D in first 7 days after hospital admission and prognosis. A total of 252 infected inpatients with T2D in China were included. Well-controlled blood glucose was defined as stable fasting blood glucose (FBG) levels in the range of 3.9-7.8 mmol/L during first 7 days using indicators of average (FBG_A), maximum (FBG_M) or first-time (FBG₁) FBG levels. The primary endpoint was admission to intensive care unit or death. Hazard ratio (HR) of poorly controlled glucose level group compared with well-controlled group were 4.96 (P = 0.021) for FBG_M and 5.55 (P = 0.014) for FBG_A. Well-controlled blood glucose levels in first 7 days could improve the prognosis of COVID-19 inpatients with diabetes.

Keywords: COVID-19; Glucose control; Prognosis analysis; Type 2 diabetes.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Blood Glucose
COVID-19*
Diabetes Mellitus, Type 2* / complications
Humans
Inpatients
Prognosis
Retrospective Studies
Risk Factors
SARS-CoV-2

Substances

Blood Glucose

Abstract

Publication types

MeSH terms

Substances

Grants and funding